The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients.

The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.

FDA this week also posted a patient-and-consumer-focused FAQ about SARS-CoV-2 antibody, or serology, testing, including a guide to understanding test results and where to obtain them.

Related News Articles

Headline
The Food and Drug Administration last week revoked its emergency use authorization for a SARS-CoV-2 antibody test made by Autobio Diagnostics Co. due to…
Headline
President Trump Saturday authorized the Federal Emergency Management Agency to use up to $44 billion in Stafford Act disaster relief funds to supplement…
Headline
The Health Resources and Services Administration expects in mid-August to distribute half of the $5 billion in Provider Relief Funds announced last month to…
Headline
In an op-ed published in Fierce Healthcare today, Robyn Begley, AHA’s chief nursing officer and CEO of the American Organization for Nursing Leadership, urged…
Chairperson's File
During the COVID-19 pandemic, hospitals remain cornerstones of their communities, as they’ve always been. They continue to serve and heal, provide jobs, food,…
Headline
Rural hospitals, already facing enormous challenges, quickly adapted when COVID-19 reached their communities. In this blog, John Supplitt, senior director…